I'm LongbridgeAI, I can summarize articles.According to a report from Economic Information Agency on the 16th, HANSOH PHARMA announced that its self-developed Class 1 new drug injectable HS-20197 has received the Clinical Trial Approval Notice from the National Medical Products Administration (NMPA) of China, intended for conducting clinical trials for "advanced solid tumors." (hp)
According to a report from Economic Information Agency on the 16th, HANSOH PHARMA (03692) announced that its self-developed Class 1 new drug injectable HS-20197 has received the clinical trial approval notice from the National Medical Products Administration (NMPA) of China, intended for conducting clinical trials for "advanced solid tumors." (hp)